头颈部多间隙感染继发下行性坏死性纵隔炎的危险因素分析

赵志国, 奚卓, 张力平. 头颈部多间隙感染继发下行性坏死性纵隔炎的危险因素分析[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(7): 645-647. doi: 10.13201/j.issn.2096-7993.2021.07.015
引用本文: 赵志国, 奚卓, 张力平. 头颈部多间隙感染继发下行性坏死性纵隔炎的危险因素分析[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(7): 645-647. doi: 10.13201/j.issn.2096-7993.2021.07.015
ZHAO Zhiguo, XI Zhuo, ZHANG Liping. Retrospective analysis of risk factors for head and neck multiple space infection with descending necrotic mediastinitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2021, 35(7): 645-647. doi: 10.13201/j.issn.2096-7993.2021.07.015
Citation: ZHAO Zhiguo, XI Zhuo, ZHANG Liping. Retrospective analysis of risk factors for head and neck multiple space infection with descending necrotic mediastinitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2021, 35(7): 645-647. doi: 10.13201/j.issn.2096-7993.2021.07.015

头颈部多间隙感染继发下行性坏死性纵隔炎的危险因素分析

详细信息

Retrospective analysis of risk factors for head and neck multiple space infection with descending necrotic mediastinitis

More Information
  • 加载中
  • 图 1  各年龄段患者分布图

    表 1  DNM构成比差异分析 例,x±s

    因素 DNM P
    否(n=173) 是(n=22)
    性别 0.91
    120 15
    53 7
    年龄/岁 53.91±15.47 66.25±17.83 0.00
    心脏病 1.00
    7 1
    166 21
    肺病 0.45
    4 1
    169 21
    高血压 1.00
    24 3
    149 19
    免疫系统疾病 1.00
    15 2
    158 20
    糖尿病 0.02
    39 10
    134 12
    下载: 导出CSV

    表 2  实验室检查结果单因素分析 x±s

    项目 非继发DNM组(n=173) 继发DNM组(n=22) P
    白细胞计数/ (×109·L-1) 13.59±4.06 13.80±4.17 0.591
    中性粒细胞百分比/% 83.10±4.61 85.50±6.08 0.990
    空腹血糖/ (mmol·L-1) 9.86±6.36 12.32±6.39 0.041
    PCT/ (ng· mL-1) 5.92±2.76 13.08±5.16 < 0.01
    CRP/(mg· L-1) 69.19±52.67 186.08±58.18 < 0.01
    下载: 导出CSV
  • [1]

    Kimura A, Miyamoto S, Yamashita T. Clinical predictors of descending necrotizing mediastinitis after deep neck infections[J]. Laryngoscope, 2020, 130(11): E567-E572.

    [2]

    陈国平, 潘忠, 叶飞, 等. 12例颈深部并下行性纵隔感染患者的诊断和治疗[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(4): 324-327. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202104009.htm

    [3]

    Razafimanjato N, Ralaizafindraibe TH, Ramarolahy AR, et al. Acute descending necrotizing mediastinitis: four years of experience at a hospital center in Madagascar[J]. Med Sante Trop, 2018, 28(3): 297-301.

    [4]

    Sakai T, Matsutani N, Ito K, et al. Deep cervical and paratracheal drainage for descending necrotizing mediastinitis[J]. Asian Cardiovasc Thorac Ann, 2020, 28(1): 29-32. doi: 10.1177/0218492319896515

    [5]

    夏韫晖, 曲禄瑶, 梁翔, 等. C反应蛋白在下行性坏死性纵隔炎中的预警作用[J]. 中国口腔颌面外科杂志, 2019, 17(3): 257-260. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGKQ201903022.htm

    [6]

    Scaglione M, Pinto A, Romano S, et al. Determining optimum management of descending necrotizing mediastinitis with CT; experience with 32 cases[J]. Emerg Radiol, 2005, 11(5): 275-280. doi: 10.1007/s10140-005-0422-3

    [7]

    许雯, 汤玮, 余少卿, 等. 颈部CT、超声与MRI对颈深部脓肿诊断价值的对比研究[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(7): 672-674. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201907024.htm

    [8]

    Bartoletti M, Antonelli M, Bruno Blasi FA, et al. Procalcitonin-guided antibiotic therapy: an expert consensus[J]. Clin Chem Lab Med, 2018, 56(8): 1223-1229. doi: 10.1515/cclm-2018-0259

    [9]

    Aloisio E, Dolci A, Panteghini M. Procalcitonin: Between evidence and critical issues[J]. Clin Chim Acta, 2019, 496: 7-12. doi: 10.1016/j.cca.2019.06.010

    [10]

    Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin(PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use[J]. Clin Chem Lab Med, 2019, 57(9): 1308-1318. doi: 10.1515/cclm-2018-1181

    [11]

    Cortegiani A, Misseri G, Ippolito M, et al. Correction to: Procalcitonin levels in candidemia versus bacteremia: a systematic review[J]. Crit Care, 2019, 23(1): 322. doi: 10.1186/s13054-019-2598-z

    [12]

    Watkins EJ, Guerrini J. Procalcitonin-guided treatment of lower respiratory tract infections[J]. JAAPA, 2018, 31(1): 50-52. doi: 10.1097/01.JAA.0000527711.69310.ae

    [13]

    Tujula B, Hämäläinen S, Kokki H, et al. Review of clinical practice guidelines on the use of procalcitonin in infections[J]. Infect Dis(Lond), 2020, 52(4): 227-234. doi: 10.1080/23744235.2019.1704860

    [14]

    Ironson G, Banerjee N, Fitch C, et al. Positive emotional well-being, health Behaviors, and inflammation measured by C-Reactive protein[J]. Soc Sci Med, 2018, 197: 235-243. doi: 10.1016/j.socscimed.2017.06.020

    [15]

    Petel D, Winters N, Gore GC, et al. Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis[J]. BMJ Open, 2018, 8(12): e022133. doi: 10.1136/bmjopen-2018-022133

    [16]

    McFadyen JD, Zeller J, Potempa LA, et al. C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond[J]. Subcell Biochem, 2020, 94: 499-520.

    [17]

    Villard MA, Helm MC, Kindel TL, et al. C-Reactive protein as a predictor of post-operative complications in bariatric surgery patients[J]. Surg Endosc, 2019, 33(8): 2479-2484. doi: 10.1007/s00464-018-6534-0

    [18]

    Tsai YW, Liu YH, Su HH. Bacteriology of peritonsillar abscess: the changing trend and predisposing factors[J]. Braz J Otorhinolaryngol, 2018, 84(5): 532-539. doi: 10.1016/j.bjorl.2017.06.007

  • 加载中

(1)

(2)

计量
  • 文章访问数:  1141
  • PDF下载数:  205
  • 施引文献:  0
出版历程
收稿日期:  2020-11-25
刊出日期:  2021-07-05

目录